Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises
December 30, 2024 08:00 AM Eastern Standard Time QUEENSBURY, N.Y.–(BUSINESS WIRE)–Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,…